Allianz SE Takes $96,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Allianz SE purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 135 shares of the biopharmaceutical company’s stock, valued at approximately $96,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of REGN. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $26,000. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 15 shares during the last quarter. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Avalon Trust Co acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $36,000. Finally, Crowley Wealth Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $36,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Robert W. Baird decreased their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Bernstein Bank lowered their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $966.88.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $634.23 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The business’s fifty day moving average price is $682.93 and its two-hundred day moving average price is $791.84. The stock has a market cap of $69.34 billion, a PE ratio of 16.57, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a one year low of $618.51 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the company earned $11.86 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.